Ranjita Shegokar Ph.D.

[smartslider3 slider="4"]

Ranjita Shegokar Ph.D, EMBA

Dr. Ranjita Shegokar holds a Ph.D. in Pharmaceutical Technology from SNDT University, India, and has completed postdoctoral research at the Free University of Berlin, Germany, specializing in Pharmaceutics, Biopharmaceutics, and NutriCosmetics. She has extensive experience in R&D leadership roles at various multinational German pharmaceutical companies and currently serves as the Chief Pharma Innovation Officer (CPO) at DiHeSys GmbH DiHeSys | Digital-Health-Systems | 2D / 3D personalisierte Medizin, Germany. She has authored numerous research articles and book chapters and has presented her work at various national and international conferences. She has filed multiple patent applications in the areas of drug delivery and targeting and has edited several influential books on pharmaceutical nanotechnology and drug delivery systems. Dr. Ranjita’s research excellence has been recognized with prestigious awards, including the German Innovation Award in 2022 and the German Medical Award in 2023. Her research interests include polymeric nanoparticles, nanocrystals, lipid nanoparticles (SLNs/NLCs), nanoemulsions, cancer drug targeting, oral solid dosage forms (OSDFs), and the role of excipients in delivery systems. Dr. Ranjita’s professional focus encompasses R&D, intellectual property, trademark, innovation strategies, preclinical development, and medical/clinical affairs.
Master's – Pharm Tech Immediate release
pediatric suppositories
Post-Doc. – Pharm Nanotech Dermal and mucosal
drug targeting : Nanoparticles
DFE Pharma GmbH & Co. KG Oral Solid Dosage Forms (OSDFs) Capnomed GmbH Drug
Targeting – conventional
/nano/micro
CapnoPharm GmbH Generic and branded oncology products
   PhD – Pharm Nanotech Drug Targeting to splenic HIV reservoirs : Nanoparticle       PharmaSol GmbH Nanocrystals- industrial production       Symrise AG Immediate & controlled active release      EMBA Business Strategy and Growth       DiHeSys GmbH 2D & 3D printing - personalized medicine  

Master's – Pharm Tech

Immediate release pediatric suppositories

PhD – Pharm Nanotech

Drug Targeting to splenic HIV reservoirs : Nanoparticle

Post-Doc. – Pharm Nanotech

Dermal and mucosal drug targeting : Nanoparticles

PharmaSol GmbH

Nanocrystals- industrial production

DFE Pharma GmbH & Co. KG

Oral Solid Dosage Forms (OSDFs)

Symrise AG

Immediate & controlled active release

Capnomed GmbH

Drug Targeting – conventional /nano/micro

EMBA

Business Strategy and Growth

CapnoPharm GmbH

Generic and branded oncology products

DiHeSys GmbH

2D & 3D printing - personalized medicine

Charged curcumin nanoparticles for aerosolization

Positively charged CUR-PLGA-NPs increased depth of tissue penetration by 81.5% and tissue concentration...

Polymer: Lipid Hybrid Nanostructures in Cancer Drug Delivery:

Liposomes, polymeric, lipid and inorganic nanoparticles have dominated and proved their clinical effectiveness...

Cancer research and therapy: Where are we today?

Advancement in cancer research and therapies is fastened by possibilities of record-breaking technologies...

Bone scaffolds: What’s new in nanoparticle drug delivery

Nanotechnology is being widely studied in bone repair or regeneration treatments in the...

Nanotoxicity: Must Consider Aspect of Nanoparticle Development

Early years are proof of nanoparticle developments and understanding basic mechanisms. With no...

Large-scale manufacturing of nanoparticles—An industrial outlook

Nanosuspensions and lipid nanoparticles are very promising drug delivery systems for overcoming drug-related...
error: Content is protected !!